pyruvaldehyde has been researched along with Atherogenesis in 21 studies
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.
methylglyoxal : A 2-oxo aldehyde derived from propanal.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atherosclerosis is a major global cause of morbidity and mortality, and diabetes patients are at increased risk of coronary heart disease development." | 2.44 | Advanced glycation: a novel outlook on atherosclerosis. ( Knight, SC; Price, CL, 2007) |
| "Coronary atherosclerosis was assessed by computed tomography coronary angiography or intravascular ultrasound." | 1.62 | Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes. ( Bech Holte, K; Bengtsson, E; Hanssen, KF; Julsrud Berg, T; Nilsson, J; Svanteson, M; Sveen, KA, 2021) |
| "The presence of both IGM and type 2 diabetes was significantly associated with higher α-dicarbonyl incremental areas under the curve (iAUCs), as calculated from the OGTT (for IGM, MGO β = 0." | 1.42 | Post-Glucose Load Plasma α-Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study. ( Hanssen, NM; Maessen, DE; Schalkwijk, CG; Scheijen, JL; Stehouwer, CD; van der Kallen, CJ; van Greevenbroek, MM, 2015) |
| "We studied THP in relation to type 1 diabetes, endothelial dysfunction, low-grade inflammation, vascular complications and atherosclerosis." | 1.39 | The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. ( Colhoun, HM; Hanssen, NM; Niessen, HW; Parving, HH; Rossing, P; Schalkwijk, CG; Schram, MT; Stehouwer, CD; Tarnow, L; van Eupen, MG, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Rehman, S | 1 |
| Song, J | 1 |
| Faisal, M | 1 |
| Alatar, AA | 1 |
| Akhter, F | 1 |
| Ahmad, S | 1 |
| Hu, B | 1 |
| Schalkwijk, CG | 6 |
| Micali, LR | 3 |
| Wouters, K | 3 |
| Nomiyama, T | 1 |
| Fang, X | 1 |
| Liu, L | 1 |
| Zhou, S | 1 |
| Zhu, M | 1 |
| Wang, B | 1 |
| Sveen, KA | 1 |
| Bech Holte, K | 1 |
| Svanteson, M | 1 |
| Hanssen, KF | 1 |
| Nilsson, J | 2 |
| Bengtsson, E | 2 |
| Julsrud Berg, T | 1 |
| Hajizadeh-Sharafabad, F | 1 |
| Sahebkar, A | 1 |
| Zabetian-Targhi, F | 1 |
| Maleki, V | 1 |
| van Eupen, MG | 1 |
| Schram, MT | 1 |
| Colhoun, HM | 1 |
| Hanssen, NM | 3 |
| Niessen, HW | 1 |
| Tarnow, L | 1 |
| Parving, HH | 1 |
| Rossing, P | 1 |
| Stehouwer, CD | 3 |
| Pouya, FD | 1 |
| Zavar-Reza, J | 1 |
| Jalali, BA | 1 |
| Titov, VN | 2 |
| Khokhlova, NV | 1 |
| Shiriaeva, IuK | 2 |
| Tikellis, C | 1 |
| Pickering, RJ | 1 |
| Tsorotes, D | 1 |
| Huet, O | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, K | 1 |
| Thomas, MC | 1 |
| Maessen, DE | 1 |
| Scheijen, JL | 1 |
| van der Kallen, CJ | 1 |
| van Greevenbroek, MM | 1 |
| Engelbertsen, D | 1 |
| Vallejo, J | 1 |
| Quách, TD | 1 |
| Fredrikson, GN | 1 |
| Alm, R | 1 |
| Hedblad, B | 1 |
| Björkbacka, H | 1 |
| Rothstein, TL | 1 |
| Wortmann, M | 1 |
| Hakimi, M | 1 |
| Fleming, T | 1 |
| Peters, AS | 1 |
| Sijmonsma, TP | 1 |
| Herzig, S | 1 |
| Nawroth, PP | 1 |
| Böckler, D | 1 |
| Dihlmann, S | 1 |
| Saremi, A | 1 |
| Howell, S | 1 |
| Schwenke, DC | 1 |
| Bahn, G | 1 |
| Beisswenger, PJ | 1 |
| Reaven, PD | 1 |
| Tikhaze, AK | 2 |
| Viigimaa, M | 1 |
| Konovalova, GG | 2 |
| Kumskova, EM | 2 |
| Abina, EA | 1 |
| Zemtsovskaya, G | 1 |
| Yanushevskaya, EV | 1 |
| Vlasik, TN | 1 |
| Lankin, VZ | 2 |
| Rabbani, N | 1 |
| Godfrey, L | 1 |
| Xue, M | 1 |
| Shaheen, F | 1 |
| Geoffrion, M | 1 |
| Milne, R | 1 |
| Thornalley, PJ | 1 |
| Aksenov, DV | 1 |
| Cantero, AV | 1 |
| Portero-Otín, M | 1 |
| Ayala, V | 1 |
| Auge, N | 1 |
| Sanson, M | 1 |
| Elbaz, M | 1 |
| Thiers, JC | 1 |
| Pamplona, R | 1 |
| Salvayre, R | 1 |
| Nègre-Salvayre, A | 1 |
| Price, CL | 1 |
| Knight, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #465FS - VA Diabetes Trial Long Term Follow-up Study[NCT00756613] | 1,044 participants (Actual) | Observational | 2008-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
End-stage renal disease, amputation for either ischemic or non-ischemic gangrene, CV-related death, or nonfatal MI, stroke, or new CHF. (NCT00756613)
Timeframe: 15 years
| Intervention | events (Number) |
|---|---|
| 465 VADT Participants - Standard | 355 |
| 465 VADT Participants -Intensive | 342 |
Self-reported health status using an instrument adapted for type 2 diabetes mellitus patients from the Diabetes Control and Complications Trial (DCCT) (Duckworth, 1998; Saudek 1996). This survey tool has been used since the inception of the VADT and will be continued in the annual survey. The minimum value is 0 and the maximum value is 100. The higher score is a better outcome. (NCT00756613)
Timeframe: 9 years
| Intervention | score on a scale (Mean) |
|---|---|
| 465 VADT Participants - Standard | 62.2 |
| 465 VADT Participants -Intensive | 63.8 |
Major CV events (non-fatal MI resulting in hospitalization, non-fatal stroke, new Congestive Heart Failure (CHF), amputation for ischemic diabetic gangrene, or CV-related death). (NCT00756613)
Timeframe: 15 years
| Intervention | number of events (Number) |
|---|---|
| 465 VADT Participants - Standard | 336 |
| 465 VADT Participants -Intensive | 325 |
The major secondary end-point of total mortality will measure all deaths with data retrieved from VA Information Resource Center (VIREC) Cooperate Data Warehouse (CDW) . Survival analysis will analyzed by time to death. (NCT00756613)
Timeframe: 15 years
| Intervention | Participants (Count of Participants) |
|---|---|
| 465 VADT Participants - Standard | 125 |
| 465 VADT Participants -Intensive | 118 |
The major secondary end-point of cardiovascular (CV) mortality will measure the cause of death (end-stage renal disease, amputation for either ischemic or non-ischemic gangrene, CV-related death, or nonfatal myocardial infarction (MI), stroke, or new congestive heart failure (CHF)) retrieved by the National Death Index (NDI). Survival analysis will analyzed by time of event to death. (NCT00756613)
Timeframe: 15 years
| Intervention | Participants (Count of Participants) |
|---|---|
| 465 VADT Participants - Standard | 366 |
| 465 VADT Participants -Intensive | 376 |
5 reviews available for pyruvaldehyde and Atherogenesis
| Article | Year |
|---|---|
Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal.
Topics: Atherosclerosis; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Magnesium Oxide; Pyruv | 2023 |
Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal.
Topics: Atherosclerosis; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Magnesium Oxide; Pyruv | 2023 |
Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal.
Topics: Atherosclerosis; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Magnesium Oxide; Pyruv | 2023 |
Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal.
Topics: Atherosclerosis; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Magnesium Oxide; Pyruv | 2023 |
The impact of resveratrol on toxicity and related complications of advanced glycation end products: A systematic review.
Topics: Animals; Antigens, Neoplasm; Antioxidants; Atherosclerosis; Diabetes Mellitus, Experimental; Gene Ex | 2019 |
[Glucose, glycotoxins, and protein glycation products: the role in pathogensis].
Topics: Atherosclerosis; Glucose; Glycation End Products, Advanced; Humans; Pyruvaldehyde | 2013 |
Methylglyoxal and glyoxalase I in atherosclerosis.
Topics: Animals; Atherosclerosis; Glycation End Products, Advanced; Humans; Lactoylglutathione Lyase; Pyruva | 2014 |
Advanced glycation: a novel outlook on atherosclerosis.
Topics: Animals; Atherosclerosis; Bacterial Infections; Cysteine Endopeptidases; Dendritic Cells; Diabetes C | 2007 |
16 other studies available for pyruvaldehyde and Atherogenesis
| Article | Year |
|---|---|
The Neoepitopes on Methylglyoxal- (MG-) Glycated Fibrinogen Generate Autoimmune Response: Its Role in Diabetes, Atherosclerosis, and Diabetic Atherosclerosis Subjects.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Female; Fibrinogen; Humans; Male; Middle Aged; Py | 2021 |
Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
Topics: Animals; Atherosclerosis; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus; | 2020 |
N‑acetylcysteine inhibits atherosclerosis by correcting glutathione‑dependent methylglyoxal elimination and dicarbonyl/oxidative stress in the aorta of diabetic mice.
Topics: Acetylcysteine; Animals; Aorta; Atherosclerosis; Diabetes Complications; Diabetes Mellitus, Experime | 2021 |
Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes.
Topics: Apolipoprotein B-100; Atherosclerosis; Autoantibodies; Coronary Artery Disease; Diabetes Mellitus, T | 2021 |
The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 1; Enzyme-Linked Immunosorbent Assay; Female; Glycat | 2013 |
In-vitro study of methylglyoxal and aspirin effects on fibrinolysis parameters.
Topics: Adult; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Fibrinolysis; Humans; Male; Pyru | 2013 |
Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Diabetes Mellitus, Experimental; Glycatio | 2014 |
Post-Glucose Load Plasma α-Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study.
Topics: Atherosclerosis; Blood Glucose; Chromatography, Liquid; Cross-Sectional Studies; Deoxyglucose; Diabe | 2015 |
Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.
Topics: Aged; Aged, 80 and over; Antibodies; Apolipoprotein B-100; Atherosclerosis; Autoantibodies; B-Lympho | 2015 |
A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Calorimetry, Indirect; Diet, High-Fat; | 2016 |
Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.
Topics: Aged; Atherosclerosis; Blood Glucose; Carotid Intima-Media Thickness; Cholesterol; Deoxyglucose; Dia | 2017 |
Interrelation between malonyl dialdehyde-dependent modification and cholesterol content in low-density lipoproteins.
Topics: Adult; Atherosclerosis; Biomarkers; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; | 2010 |
Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.
Topics: Animals; Aorta; Apolipoprotein B-100; Apolipoproteins E; Atherosclerosis; Cardiovascular Diseases; C | 2011 |
[The glucose, glycotoxins and glycation products: the involvement into pathogenesis of microangiopathies, arteriolosclerosis and atherosclerosis].
Topics: Arteriolosclerosis; Atherosclerosis; Diabetes Mellitus; Diabetic Angiopathies; Glucose; Glutamic Aci | 2011 |
[The role of oxidative processes in augmentation of atherogenity of low density lipoprotein particles].
Topics: Apolipoprotein B-100; Atherosclerosis; Blood Protein Electrophoresis; Free Radicals; Humans; Hypergl | 2012 |
Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis.
Topics: Animals; Aorta; Apolipoproteins E; Arginine; Atherosclerosis; Becaplermin; Cell Movement; Cell Proli | 2007 |